Alterity Therapeutics Prominently Featured at the International MSA Congress

– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints –

– MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring –

Read more at globenewswire.com